73573-87-2 Usage
Chemical Properties
solid
Uses
Different sources of media describe the Uses of 73573-87-2 differently. You can refer to the following data:
1. Labeled Formoterol, intended for use as an internal standard for the quantification of Formoterol by GC- or LC-mass spectrometry.
2. Formoterol is a useful compound for treating respiratory obstructive diseases.
Definition
ChEBI: A phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent.
Brand name
Foradil (Novartis).
General Description
Formoterol (Foradil) isalso a lipophilic (log P= 1.6) and long-acting β2-agonist. Ithas 3'-formylamino ( β-directing) and 4 OH groups on onephenyl ring and a lipophilic -directing N-isopropyl-pmethoxyphenylgroup on the nitrogen atom. Its long DOA(12 hours), which is comparable to that of salmeterol, hasbeen suggested to result from its association with the membranelipid bilayer, from which it gradually diffuses to provideprolonged stimulation of β2 receptors and its resistanceto MAO and COMT. Formoterol has a much faster onset ofaction than does salmeterol as result of its lower lipophilicity.Both of these long-acting drugs are used by inhalationand are recommended for maintenance treatment of asthma,usually in conjunction with an inhaled corticosteroid.
Mechanism of action
Formoterol has 3′-formylamino and 4′-hydroxy ring R3
substitution pattern but also an alkoxyphenylethyl lipophilic group R1
on the nitrogen, similar to ritodrine. Although
it is less lipophilic (log P = 1.6) than salmeterol, it has a 12-hour duration of action similar to that for salmeterol. It is administered as an inhaled dry powder, because it
is unstable to heat and moisture. It is a mixture of (R,R)-(–)- and (S,S)-(+)-stereoisomers, with the (R,R)-isomer having approximately 1,000-fold more affinity for the
β2-receptor than the (S,S)-isomer. Because of its high potency and low dose, however, there is no clinical advantage for using (R,R)-formoterol as bronchodilator
compared to the racemate. Unlike salmeterol, formoterol has a faster onset of action as a result of its lower lipophilicity. It is also more potent; a 12-μg dose of
formoterol has been demonstrated to be equivalent to a 50-μg dose of salmeterol.
Check Digit Verification of cas no
The CAS Registry Mumber 73573-87-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,5,7 and 3 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 73573-87:
(7*7)+(6*3)+(5*5)+(4*7)+(3*3)+(2*8)+(1*7)=152
152 % 10 = 2
So 73573-87-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)
73573-87-2Relevant articles and documents
PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF
-
, (2016/04/19)
Provided is an improved process for the preparation of arformoterol L-(+)-tartrate, and more specifically provided is a novel process for the preparation of arformoterol L-(+)-tartrate via arformoterol D-(?)-tartrate.
Process for preparation of intermediates of arformoterol
-
, (2011/08/07)
An improved method for the preparation of optically pure isomers of Formoterol is disclosed, particularly the (R,R)-isomer.A method of preparation of substantially enantiomerically pure (R,R)-1-(4-Benzyloxy-3-nitro-phenyl)-2-[[2-(4-methoxy-phenyl)-1-methyl-ethyl]-(1-phenyl-ethyl)-amino]-ethanol to use in the production of (R,R)-Formoterol is also disclosedAn improved method for the preparation of optically pure isomers of Formoterol is disclosed, particularly the (R,R)-isomer. A method of preparation of substantially enantiomerically pure (R,R)-1-(4-Benzyloxy-3-nitro-phenyl)-2-[[2-(4-methoxy-phenyl)-1-methyl-ethyl]-(1-phenyl-ethyl)-amino]-ethanol to use in the production of (R,R)-Formoterol is also disclosed
PROCESS FOR THE SYNTHESIS OF ARFORMOTEROL
-
, (2009/12/28)
The present invention provides a process for preparing a compound of formula (Vl) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no isolation of an imine intermediate formed during the reductive amination; (ii) condensing the compound (II) or the acid addition salt thereof with an α-haloketone of formula (III) to produce the compound of formula (IV); (iii) reducing the compound (IV) to a compound of formula (V); and (iv) reducing the compound (V) to the compound of formula (Vl), wherein the reduction is carried out in the presence of either (1 ) a hydrogen donating compound in the presence of a hydrogen transfer catalyst; or (2) ammonium formate using a hydrogenation catalyst, wherein: R1 and R2 are independently optionally substituted arylalkyl, and Hal is selected from chloro or bromo.
